Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB)

Historical Holders from Q1 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
INMB on Nasdaq
Shares outstanding
27,969,231
Price per share
$1.46
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
4,653,422
Holdings value
$9,631,501
% of all portfolios
0%
Share change
-972,627
Value change
-$1,934,721
Average buys %
+0%
Average sells %
-0%
Number of holders
72
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC 5.2% $3,359,664 1,454,400 Highbridge Capital Management, LLC 30 Jun 2025
CVI Investments, Inc. 4.9% -10% $3,225,404 -$239,596 1,396,279 -6.9% CVI Investments, Inc. 30 Jun 2025
Praetorian PR LLC 3.4% -54% $2,127,972 -$1,700,160 921,200 -44% Kupperman Harris 30 Jun 2025
As of 30 Sep 2025, Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) has 72 institutional shareholders filing 13F forms. They hold 4,653,422 shares of 27,969,231 outstanding shares (17%) .

Top 25 institutional shareholders own 16% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 4.2% 1,186,876 +1.2% 0% $2,456,833
VANGUARD GROUP INC 3.1% 876,292 +3.4% 0% $1,813,924
GEODE CAPITAL MANAGEMENT, LLC 1.7% 469,440 +20% 0% $972,014
STATE STREET CORP 1% 283,833 +3.1% 0% $587,534
RAYMOND JAMES FINANCIAL INC 0.96% 268,460 -19% 0% $555,712
NORTHERN TRUST CORP 0.68% 189,116 +15% 0% $391,470
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.56% 156,954 +687% 0% $324,895
UBS Group AG 0.56% 155,522 -65% 0% $321,930
Westside Investment Management, Inc. 0.37% 103,450 +384% 0.03% $214,150
MORGAN STANLEY 0.27% 75,710 -26% 0% $156,720
DEUTSCHE BANK AG\ 0.22% 61,712 +20749% 0% $127,744
Bank of New York Mellon Corp 0.21% 59,851 -2.8% 0% $123,892
JPMORGAN CHASE & CO 0.21% 57,714 -21% 0% $119,468
JANE STREET GROUP, LLC 0.18% 49,574 0% $102,618
XTX Topco Ltd 0.17% 48,744 -61% 0.01% $100,900
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.15% 41,825 -19% 0% $86,578
Focus Partners Advisor Solutions, LLC 0.15% 40,950 -16% 0% $84,767
GROUP ONE TRADING LLC 0.14% 38,584 0% $79,869
PNC Financial Services Group, Inc. 0.14% 38,387 +1.8% 0% $79,461
BARCLAYS PLC 0.11% 30,006 -21% 0% $62,112
WOLVERINE TRADING, LLC 0.1% 29,193 0% $61,597
Laird Norton Wetherby Trust Company, LLC 0.09% 25,000 -32% 0.01% $51,750
RHUMBLINE ADVISERS 0.08% 22,649 +1.4% 0% $46,875
ALLIANCEBERNSTEIN L.P. 0.08% 21,950 0% 0% $45,437
Cambridge Investment Research Advisors, Inc. 0.08% 21,375 -34% 0% $44,000

Institutional Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 1,181 $1,643 +$282 $1.46 2
2025 Q3 4,653,422 $9,631,501 -$1,934,721 $2.07 72
2025 Q2 5,623,690 $12,725,267 -$10,010,248 $2.31 78
2025 Q1 6,162,475 $48,114,521 -$163,536 $7.81 81
2024 Q4 6,324,914 $29,538,643 +$2,163,001 $4.67 72
2024 Q3 5,352,153 $28,834,750 +$6,030,346 $5.39 65
2024 Q2 4,566,933 $40,279,815 +$15,412,868 $8.82 56
2024 Q1 2,738,821 $32,179,382 +$5,308,168 $11.75 50
2023 Q4 2,292,004 $25,807,938 +$1,854,241 $11.26 47
2023 Q3 2,133,529 $14,477,326 -$5,887,298 $6.77 36
2023 Q2 2,186,070 $24,850,986 +$8,529,775 $9.08 32
2023 Q1 1,804,387 $11,657,371 +$1,101,433 $6.46 33
2022 Q4 1,645,407 $10,430,707 -$728,047 $6.34 32
2022 Q3 1,912,551 $11,855,780 -$744,186 $6.20 32
2022 Q2 2,010,894 $17,633,536 -$2,412,787 $8.84 34
2022 Q1 2,294,234 $19,315,368 -$2,106,118 $8.42 32
2021 Q4 2,484,556 $25,343,080 +$4,757,601 $10.20 42
2021 Q3 1,942,445 $37,703,608 +$4,889,864 $19.42 40
2021 Q2 1,710,752 $30,053,028 +$8,038,213 $17.57 39
2021 Q1 1,305,763 $15,492,692 +$5,444,483 $11.88 32
2020 Q4 793,136 $13,655,776 +$1,189,170 $17.21 25
2020 Q3 992,741 $10,252,248 +$6,463,618 $10.30 27
2020 Q2 358,561 $1,881,000 +$104,639 $5.17 11
2020 Q1 342,213 $1,139,000 +$200,616 $3.32 9
2019 Q4 282,367 $1,637,000 +$40,401 $5.80 9
2019 Q3 274,538 $1,620,000 +$1,390,869 $5.90 9
2019 Q2 38,466 $373,000 -$43,981 $9.72 7
2019 Q1 45,117 $352,000 +$352,000 $7.44 5